KIT was the most common mutation, followed by TET2, NRAS, FLT3-ITD, NPM1, and DNMT3A. Eleven (26.8%) of 41 patients with myeloid sarcoma had at least two gene mutations. This evidence concerns the gene TET2 and myeloid sarcoma.